Effects of HQK-1001 in Patients With Sickle Cell Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

December 31, 2013

Conditions
Sickle Cell DiseaseSickle Cell AnemiaSickle Cell DisordersHemoglobin S DiseaseSickling Disorder Due to Hemoglobin S
Interventions
DRUG

HQK-1001

HQK-1001 tablets, twice daily for 48 weeks

DRUG

Placebo

Placebo tablets, twice daily for 48 weeks

Trial Locations (18)

10467

The Children's Hospital at Montefiore Medical Center, The Bronx

11215

New York Methodist Hospital, Brooklyn

20010

Children's National Hospital, Washington D.C.

20060

Howard University Hospital, Washington D.C.

23298

Virginia Commonwealth Univeristy - Center on Health Disparities, Richmond

27599

University of North Carolina at Chapel Hill, Chapel Hill

30912

Georgia Health Sciences University, Augusta

60612

University of Illinois at Chicago, Chicago

94609

Children's Hospital and Research Center - Oakland, Oakland

36617-2238

University of South Alabama, Mobile

02111

Tufts Medical Center, Boston

M5G2C4

University Health Network Toronto General Hospital, Toronto

Unknown

Abu El Reesh Pediatric University Hospital, Cairo

Ain Sham University Hospital, Cairo

University of the West Indies, Mona, Kingston 7

American University of Beirut Medical Center, Beirut

Chronic Care Center, Beirut

Rafik Hariri University Hospital, Beirut

Sponsors
All Listed Sponsors
lead

HemaQuest Pharmaceuticals Inc.

INDUSTRY